FHL5

Across TCGA pan-cancer cohorts, FHL5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FHL5 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FHL5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FHL5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where FHL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.850	0.632	<.001	87	view →
LUAD	DFS	Median	II,III,IV	0.665	0.990	.002	27	view →
LSCC	DFS	Quartile	All	0.884	1.000	.014	8	view →
GBM	DFS	Tertile	All	0.845	0.609	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FHL5–PDAC (DFS)

Open the PDAC breakdown →